Association Between Proton Pump Inhibitor Therapy and Clostridium difficile Infection in a Meta-Analysis

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 3, 2012, Pages 225-233

  Deshpande, Abhishek ^a   Pant, Chaitanya ^b   Pasupuleti, Vinay ^a   Rolston, David D K ^c   Jain, Anil ^a   Deshpande, Narayan ^d   Thota, Priyaleela ^a   Sferra, Thomas J ^b   Hernandez, Adrian V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c GEISINGER MEDICAL CENTER   (United States)

^d Bhaskar Medical College   (India)

Author keywords

Bacteria; Gastric Acid Suppression; Infectious Diarrhea; Systematic Analysis

Indexed keywords

PROTON PUMP INHIBITOR;

CLOSTRIDIUM DIFFICILE INFECTION; DATA EXTRACTION; DRUG USE; HUMAN; META ANALYSIS; QUALITY CONTROL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; PROTON PUMP INHIBITORS; RISK ASSESSMENT;

EID: 84857189040     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.09.030     Document Type: Review

References (49)

1. McFarland L.V. Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients. Am J Infect Contr 1995, 23:295-305.
2. Zilberberg M.D., Shorr A.F., Kollef M.H. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008, 14:929-931.
3. Kyne L., Hamel M.B., Polavaram R., et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002, 34:346-353.
4. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441.
5. Cohen M.B. Clostridium difficile infections: emerging epidemiology and new treatments. J Pediatr Gastroenterol Nutr 2009, 48(Suppl 2):S63-S65.
6. Deshpande A., Pant C., Jain A., et al. Do fluoroquinolones predispose patients to Clostridium difficile associated disease?. A review of the evidence. Curr Med Res Opin 2008, 24:329-333.
7. Pant C., Madonia P., Minocha A. Does PPI therapy predispose to Clostridium difficile infection?. Nat Rev Gastroenterol Hepatol 2009, 6:555-557.
8. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
9. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
10. Klok R.M., Postma M.J., van Hout B.A., et al. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003, 17:1237-1245.
11. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
12. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
13. Dial S., Alrasadi K., Manoukian C., et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004, 171:33-38.
14. Williams C., McColl K.E. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006, 23:3-10.
15. Howell M.D., Novack V., Grgurich P., et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010, 170:784-790.
16. Walker K.J., Gilliland S.S., Vance-Bryan K., et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc 1993, 41:940-946.
17. Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007, 102:2047-2056. quiz, 2057.
18. Janarthanan S., Ditah I., Kutait A., et al. A meta-analysis of 16 observational studies on proton pump inhibitor use and risk of Clostridium difficile associated diarrhea. Am J Gastroenterol 2009, 105(Suppl 1):S139.
19. Shukla S., Shukla A., Guha S., et al. Use of proton pump inhibitors and risk of Clostridium difficile-associated diarrhea: a meta-analysis. Gastroenterology 2010, 138(Suppl 1):S-209.
20. Dalton B.R., Lye-Maccannell T., Henderson E.A., et al. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther 2009, 29:626-634.
21. Caos A., Breiter J., Perdomo C., et al. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther 2005, 22:193-202.
22. Bianchi Porro G., Lazzaroni M., Imbesi V., et al. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. Dig Liver Dis 2000, 32:201-208.
23. Dyspepsia: managing dyspepsia in adults in primary care. North of England Dyspepsia Guideline Development Group. NICE Clinical Guidelines, No. 17 2004, NHS National Institute of Health and Clinical Excellence.
24. Shah S., Lewis A., Leopold D., et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000, 93:175-181.
25. Yip C., Loeb M., Salama S., et al. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001, 22:572-575.
26. Cunningham R., Dale B., Undy B., et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003, 54:243-245.
27. Al-Tureihi F.I., Hassoun A., Wolf-Klein G., et al. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc 2005, 6:105-108.
28. Dial S., Delaney J.A., Barkun A.N., et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
29. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
30. Modena S., Bearelly D., Swartz K., et al. Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study. Infect Control Hosp Epidemiol 2005, 26:685-690.
31. Muto C.A., Pokrywka M., Shutt K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280.
32. Gillis C., Fardy J., Hutchinson J. Proton pump inhibitors: are they a risk factor for Clostridium difficile diarrhea: a case-control study. Gastroenterology 2006, 20(Suppl A):191.
33. Kazakova S.V., Ware K., Baughman B., et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006, 166:2518-2524.
34. Lowe D.O., Mamdani M.M., Kopp A., et al. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006, 43:1272-1276.
35. Yearsley K.A., Gilby L.J., Ramadas A.V., et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006, 24:613-619.
36. Akhtar A.J., Shaheen M. Increasing incidence of Clostridium difficile-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy. J Natl Med Assoc 2007, 99:500-504.
37. Beaulieu M., Williamson D., Pichette G., et al. Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol 2007, 28:1305-1307.
38. Branch K., Yahl V., Kier K., et al. Gastric acid suppression by proton pump inhibitors as an independent risk factor for Clostridium difficile-associated diarrhea. Pharmacol Ther 2007, 32:4.
39. Cadle R.M., Mansouri M.D., Logan N., et al. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007, 64:2359-2363.
40. Dubberke E.R., Reske K.A., Yan Y., et al. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007, 45:1543-1549.
41. Jayatilaka S., Shakov R., Eddi R., et al. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci 2007, 37:241-247.
42. McFarland L.V., Clarridge J.E., Beneda H.W., et al. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis 2007, 45:1141-1151.
43. Aseeri M., Schroeder T., Kramer J., et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008, 103:2308-2313.
44. Baxter R., Ray G.T., Fireman B.H. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008, 29:44-50.
45. Dial S., Kezouh A., Dascal A., et al. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008, 179:767-772.
46. Kim J.W., Lee K.L., Jeong J.B., et al. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol 2010, 16:3573-3577.
47. Kim Y.G., Jang B.I., Choi E.J., et al. Association of proton pump inhibitors with recurrent Clostridium difficile associated disease: a matched case-control analysis by using propensity score (abstr). Gastroenterology 2010, 138(Suppl 1):S-209.
48. Linsky A., Gupta K., Lawler E.V., et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010, 170:772-778.
49. Linney S., Fernandes T., Einarson T., et al. Association between use of proton pump inhibitors and a Clostridium difficile-associated disease outbreak: case-control study. Can J Hosp Pharm 2010, 63:8.